AMEX · Medical - Pharmaceuticals

Nasus Pharma Ltd. (NSRX) Stock

$3.51 -3.31% AMEX: NSRX Healthcare

Valuation

MetricValue
Price$3.51
Market Cap$30.23M
P/E Ratio-3.34
P/B Ratio3.50
P/S Ratio0.00
EPS (TTM)$-0.17
52-Week High$9.50
52-Week Low$1.98
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-158.83%
ROA-87.81%
ROCE-96.93%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.01
Current Ratio8.77

Annual Financials (USD)

Metric2022202320242025
Revenue$0$0$0$0
Operating Profit$-2.0M$-1.0M$-1.0M$-5.0M
Net Profit$-2.0M$-1.0M$-2.0M$-6.0M
EPS$-0.19$-0.12$-0.17$-0.72
Op Margin————

Balance Sheet (USD)

Metric2022202320242025
Total Assets———$5.0M
Total Liabilities———$2.0M
Cash———$1.0M
Borrowings$0$0$0$0

Latest News

OTC Markets Life Sciences Investor Forum: Dan Teleman, CEO, and Eyal Rubin, SVP and CFO, of Nasus Pharma with Zacks SCR's John Vandermosten, CFA Zacks Small Cap Research · Jul 7, 2026 Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing GlobeNewswire · Jun 26, 2026 Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th GlobeNewswire · Jun 23, 2026 NSRX: NS002 June KOL Event Zacks Small Cap Research · Jun 22, 2026 Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum GlobeNewswire · Jun 22, 2026

Cash Flow (USD)

Metric2022202320242025
Operating Cash Flow$-1.0M$-1.0M$-1.0M$-5.0M
Investing Cash Flow$0$0$0$-3.0M
Financing Cash Flow$0$0$0$0
Net Cash Flow$0$0$0$1.0M
Free Cash Flow$-1.0M$-1.0M$-1.0M$-5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.03
EV / EBITDA-3.10
FCF Yield-11.22%
Quick Ratio8.77
Interest Coverage0.00
Return 1Y-49.13%
Return 3Y—
Return 5Y—

Ownership

Insiders Held49.17%
Institutions Held18.57%
Institutions Float Held36.52%
Institutional HolderSharesReport Date
Balyasny Asset Management LP898,4732026-03-31
Cable Car Capital, LP601,9982026-03-31
Velan Capital Investment Management LP359,3902026-03-31
Hudson Bay Capital Management Lp134,7712026-03-31
Bleichroeder LP89,8482026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACETAdicet Bio, Inc. $5.61 -2.26% -0.57 $52.44M 0.00%
ACRVAcrivon Therapeutics, Inc. $1.91 +2.14% -1.12 $81.75M 0.00%
ADAGAdagene Inc. $3.67 +1.66% -7.78 $138.17M 0.00%
CRVOCervoMed Inc. $3.22 -1.83% -0.94 $29.81M 0.00%
FBIOFortress Biotech, Inc. $2.13 +2.15% 0.64 $70.92M 0.00%

About Nasus Pharma Ltd.

Nasus Pharma Ltd. is led by CEO Dan Teleman, employs 2 people, headquartered in IL, publicly traded since 2025.

Nasus Pharma Ltd. (NSRX) stock trades at $3.51 with a market capitalization of $30.23M. The stock is valued at a price-to-earnings (P/E) ratio of -3.34, price-to-book of 3.50, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.98 and $9.50, and currently trades 63.1% below its 52-week high.

On profitability, Nasus Pharma Ltd. generates a return on equity (ROE) of -158.83%, return on capital employed of -96.93%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides